A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
Phase 3
- Conditions
- Gastric Cancer
- Registration Number
- JPRN-jRCT2080220416
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Inclusin criteria:
- adult patients, >=18 years of age
- inoperable, locally advanced or metastatic cancer of stomach or gastro-esophageal junction
- measurable or non-measurable but evaluable disease
- ECOG PS of 0, 1 or 2
Exclusion criteria:
- previous chemotherapy for locally advanced or metastatic gastric cancer
- previous platinum or anti-angiogenic therapy
- patients with locally advanced disease who are candidates for curative therapy
- radiotherapy within 28 days of randomisation
- evidence of CNS metastasis
- inadequate organ function
- history of bleeding or wound-healing complications
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method